RESUMEN
OBJECTIVE: Many pieces of literature have reported that inherited and acquired thrombophilia might be a risk factor for recurrent implantation failure (RIF), however, most studies have only focused on RIF patients and not their male partners. We studied the possible association of paternal thrombophilia with RIF risk. METHODS: Forty-two male partners aged 20-45 suffered from RIF compared with 42 males from couples with at least one successful pregnancy. All participants were investigated for thrombophilia markers. RESULTS: The prevalence of coagulation Factor V activity was significantly higher in the case group (42.9%) than in the control group (16.7%) (p=0.008) (OR=3.75; 95% CI, 1.38, 10.12). The prevalence of protein C and protein S deficiencies in RIF patients were 4.8% and 2.4%, respectively, and 0% in the controls. The prevalence of antithrombin III (ATIII) deficiency was significantly higher in the case group (19%) than in the control group (2.4%) (p=0.01). None of MTHFR C677T and MTHFR A1298C were statistically significant between the two groups. Combined thrombophilia was 45.2% in the men of the RIF group when compared with the control, 14.2% (p=0.001) (OR = 4.95; 95% CI, 1.75-13.86). CONCLUSIONS: Paternal thrombophilia may be related to recurrent implantation failure, so evaluation of this factor in RIF patients could be used to identify relevant risk groups and may help in the proper management of these cases to enhance the chance of implantation.
Asunto(s)
Trombofilia , Humanos , Masculino , Trombofilia/epidemiología , Adulto , Estudios de Casos y Controles , Femenino , Persona de Mediana Edad , Implantación del Embrión , Adulto Joven , Embarazo , Factores de RiesgoRESUMEN
La púrpura fulminante o purpura fulminans es un síndrome de trombosis microvascular cutánea y necrosis hemorrágica de rápida evolución. Se presenta el caso de un paciente masculino, internado por patología infecciosa y evento cardiovascular agudo, que desarrolla púrpura fulminante por déficit de proteína C, relacionado a cuadro infeccioso concomitante.
Purpura fulminans is a rapidly evolving syndrome of cutaneous microvascular thrombosis and hemorrhagic necrosis. We present the case of a male patient, hospitalized for an infectious pathology and an acute cardiovascular event, who developed purpura fulminans due to protein C deficiency, related to a concomitant infectious condition.
RESUMEN
SUMMARY OBJECTIVE: Cardiovascular disease risk prediction in scleroderma is important. In this study of scleroderma patients, the aim was to investigate the relationship between cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide and cardiovascular disease risk with the Systematic COronary Risk Evaluation 2 model of the European Society of Cardiology. METHODS: Systematic COronary Risk Evaluation 2 risk groups of 38 healthy controls and 52 women with scleroderma were evaluated. Cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide levels were analyzed with commercial ELISA kits. RESULTS: In scleroderma patients, cardiac myosin-binding protein-C and trimethylamine N-oxide levels were higher than healthy controls but sensitive troponin T was not (p<0.001, p<0.001, and p=0.274, respectively). Out of 52 patients, 36 (69.2%) were at low risk, and the other 16 (30.8%) patients were at high-moderate risk with the Systematic COronary Risk Evaluation 2 model. At the optimal cutoff values, trimethylamine N-oxide could discriminate high-moderate risk with sensitivity 76%, specificity 86% and cardiac myosin-binding protein-C with sensitivity 75%, specificity 83%. Patients with high trimethylamine N-oxide levels (≥10.28 ng/mL) could predict high-moderate- Systematic COronary Risk Evaluation 2 risk 15 times higher than those with low trimethylamine N-oxide (<10.28 ng/mL) levels (odds ratio [OR]: 15.00, 95%CI 3.585-62.765, p<0.001). Similarly, high cardiac myosin-binding protein-C (≥8.29 ng/mL) levels could predict significantly higher Systematic COronary Risk Evaluation 2 risk than low cardiac myosin-binding protein-C (<8.29 ng/mL) levels (OR: 11.00, 95%CI 2.786-43.430). CONCLUSION: Noninvasive cardiovascular disease risk prediction indicators in scleroderma, cardiac myosin-binding protein-C, and trimethylamine N-oxide could be recommended to distinguish between high-moderate risk and low risk with the Systematic COronary Risk Evaluation 2 model.
RESUMEN
INTRODUCTION: There is a high incidence of venous thromboembolism (VTE) in patients with Multiple Myeloma (MM), however; until now, the exact mechanisms behind VTE in MM are unknown, and some of the elements that may play a significant role are the treatment with an immunomodulator (IMiD) and acquired resistance to activated protein C (APC). OBJECTIVE: The study aims to reveal the possible mechanisms linked to the reduced antithrombotic activity of APC associated with thalidomide. METHODS: The molecular docking approach was used to ascertain the in silico inhibitory potential of thalidomide on the APC protease domain in the architecture of the catalytic triad and its interaction with major substrate binding sites. RESULTS: The coupling showed that the inhibitory activity of thalidomide depends on the induction of structural changes in the protease domain of APC, at the level of the Ser/His/Asp catalytic triad, as a result of a significant increase between the distances of CαAsp102 and Cα Ser195 (11.175 angstroms, increase 14.83%) and between CαSer195 and CαHis57 (9.478 angstroms, increase 13.78 %). This can result in an inefficient transfer of the proton between these residues, the other possible mechanism of inhibition, is a potential reduced binding of the substrate as a result of a direct interaction through a carbon-hydrogen bond on His57, an H-bond on Arg306, and a carbon hydrogen bond on Arg506. CONCLUSION: We demonstrate the in silico inhibitory potential of thalidomide on APC, through two possible inhibition mechanisms, a pathophysiologically relevant finding to understand the factors that can affect the stability and functions of APC in vivo.
Asunto(s)
Resistencia a la Proteína C Activada , Mieloma Múltiple , Tromboembolia Venosa , Humanos , Talidomida/efectos adversos , Resistencia a la Proteína C Activada/inducido químicamente , Resistencia a la Proteína C Activada/complicaciones , Tromboembolia Venosa/complicaciones , Simulación de Dinámica Molecular , Simulación del Acoplamiento Molecular , Péptido HidrolasasRESUMEN
BACKGROUND: Patients with inherited pulmonary surfactant metabolism disorders have a wide range of clinical outcomes and imaging findings. Response to current anti-inflammatory therapies has been variable and efficacy is unclear. OBJECTIVE: To describe and compare genetic, clinical, histological, and computed tomography (CT) outcomes in a cohort of patients with variants in the genes encoding surfactant protein C (SP-C) or adenosine triphosphate-binding cassette transporter A3 (ABCA3) in Argentina. METHODS: Observational cohort retrospective study. Patients carrying variants in genes encoding SP-C and ABCA3 proteins were included. RESULTS: Fourteen patients met the inclusion criteria: SFTPC n = 6, ABCA3 n = 8 (seven were heterozygous and one compound heterozygous). Neonatal respiratory distress was more frequent and severe in neonates with variants in the ABCA3 gene. The onset of the disease occurred in infancy before the age of 20 months in all cases. Patients with ABCA3 pathogenic variants had a severe clinical course, while long-term outcomes were more favorable in individuals with SFTPC variants. Initial CT findings were ground glass opacities and intraparenchymal cysts in both groups. Over time, signs of lung fibrosis were present in 57% of patients with ABCA3 variants and in 33% of the SFTPC group. The efficacy of anti-inflammatory interventions appears to be poor, especially for patients with ABCA3 pathogenic variants. CONCLUSIONS: Clinical, histological, and radiological features are similar in patients with SFTPC and ABCA3 variants; however, the latter have more severe clinical course. Current anti-inflammatory regimens do not appear to stop the progression of the disease.
Asunto(s)
Surfactantes Pulmonares , Recién Nacido , Humanos , Lactante , Tensoactivos , Estudios Retrospectivos , Argentina , Proteína C Asociada a Surfactante Pulmonar/genética , Mutación , Progresión de la Enfermedad , Transportadoras de Casetes de Unión a ATP/genéticaRESUMEN
Introducción: Las enfermedades Cerebrovasculares constituyen un importante problema de salud a escala global y en Cuba ocupan la tercera causa de muerte y la primera causa de discapacidad. Objetivo: Evaluar el uso de atorvastatina en el infarto cerebral aterotrombótico agudo. Métodos: Se realizó un estudio prospectivo longitudinal en los pacientes que acudieron al cuerpo de guardia del Hospital Clínico Quirúrgico Julio Trigo López diagnosticados como infarto cerebral aterotrombótico agudo. De forma aleatoria y con previo consentimiento informado se les suministró una dosis de 0, 20 mg o 40 mg de atorvastatina. Se les realizó tomografía axial computarizada de cráneo, la cual fue repetida al tercer día y a los 30 días. Se determinó el valor de proteína C reactiva en el cuerpo de guardia, y a los 30 días fueron evaluados clínicamente de acuerdo a la escala de National Institute of Health Stroke Scale en cuerpo de guardia, diariamente durante su ingreso y 30 días después. Resultados: El tamaño del área infartada disminuyó un 19,4 por ciento con 40 mg de atorvastatina al igual que el valor de proteína C reactiva que se redujo en 16 mg/L. La evaluación clínica según la escala de National Institute of Health Stroke Scale mostró una reducción en más de 8 puntos de acuerdo a la dosis de atorvastatina empleada. Conclusiones: Se demostró la eficacia de la atorvastatina por la disminución del área infartada, la reducción de los valores de proteína C reactiva y la evolución clínica favorable. Todos estos factores fueron directamente proporcional a la dosis de atorvastatina empleada(AU)
Introduction: Cererovascular diseases represent an important health problem worldwide and in Cuba they rank the third cause of death and the first cause of disability. Objective: To evaluate the use of astorvastin in acute atherotrombotic cerebral infactation. Methods: A longitudinal prospective study was carried out in patients who attended the emergency room of Julio Trigo López Surgical Clinical Hospital diagnosed with acute atherothrombotic cerebral infarction. Randomly and with prior informed consent, they were given a dose of 0, 20 mg or 40 mg of atorvastatin. Computerized axial tomography of the skull was performed, which was repeated on day 3 and day 30. The value of C-reactive protein in the emergency room was determined, and at day 30, they were clinically evaluated daily during admission and 30 days later, according to the scale of the National Institute of Health Stroke Scale in emergency room. Results: The size of the infarcted area decreased by 19.4 percent with 40 mg of atorvastatin, as well as the value of C-reactive protein, which decreased by 16 mg/L. The clinical evaluation according to the National Institute of Health Stroke Scale showed reduction of more than 8 points according to the dose of atorvastatin used. Conclusions: The efficacy of atorvastatin was demonstrated by the reduction of the infarcted area, the reduction of C-reactive protein values and the favorable clinical evolution. All of these factors were directly proportional to the dose of atorvastatin used(AU)
Asunto(s)
Humanos , Masculino , Femenino , Proteína C , Infarto Cerebral/epidemiología , Atorvastatina/uso terapéutico , Estudios Prospectivos , Estudios LongitudinalesRESUMEN
RESUMEN: Presentamos el caso clínico de un varón de 58 años de edad, con trombosis por déficit de Proteína C y S, tras descartar proceso secundario, inmunológico y oncológico.
ABSTRACT: We present the clinical case of a 58-year-old man with protein C and S deficiency thrombosis, after ruling out secondary, immunological and oncological processes.
Asunto(s)
TrombosisRESUMEN
OBJECTIVE: To clarify the incidence and genetic risk of neonatal-thromboembolism, we conducted a nationwide study exploring the impact of thrombophilia on neonatal-thromboembolism in Japan. STUDY DESIGN: A questionnaire survey was conducted for perinatal centers in Japan, focusing on the clinical expression, genotype, treatment, and outcome of patients who developed thromboembolism within 28 days of birth from 2014 to 2018. RESULTS: The estimated incidence of neonatal-thromboembolism was 0.39 cases per 10 000 live births. Intracranial lesions and purpura fulminans occurred in 66 and 5 of 77 patients, respectively. Fifty-eight (75.3%) infants presented within 3 days after birth. Four (5.2%) died, and 14 (18.2%) survived with disability. At the diagnosis, <20% plasma activity of protein C was noted in 16 infants, protein S (in 2), and antithrombin (in 1). Thirteen genetic tests identified 4 biallelic and 5 monoallelic protein C-variants but no protein S- or antithrombin-variants. Protein C-variants had purpura fulminans (P < .01), ocular bleeding (P < .01), positive-family history (P = .01), and death or disability (P = .03) more frequently than others. Protein C-variants were independently associated with disability (OR 5.74, 95% CI 1.16-28.4, P = .03) but not death. Four biallelic variants had serious thrombotic complications of neurologic disability, blindness, and/or amputation. Three monoallelic variants survived without complications. The only protein C-variant death was an extremely preterm heterozygote infant. CONCLUSIONS: Monoallelic protein C-variants had a higher incidence of neonatal-thromboembolism than biallelic variants. Thrombophilia genetic testing should be performed in the setting of neonatal-thromboembolism and low protein C to identify the underlying genetic defect.
Asunto(s)
Deficiencia de Proteína C/complicaciones , Tromboembolia/epidemiología , Femenino , Predisposición Genética a la Enfermedad , Humanos , Recién Nacido , Japón , Masculino , Deficiencia de Proteína C/genética , Estudios Retrospectivos , Factores de Riesgo , Encuestas y Cuestionarios , Tromboembolia/genéticaRESUMEN
In order to investigate the possible correlation between p53 and MDM2 co-expression with clinicopathological features of differentiated thyroid cancer (DTC) and its use as diagnostic and/or prognostic markers, we used immunohistochemistry to evaluate 317 thyroid samples including 208 DTC and 94 benign nodules, in addition to 15 normal tissues. MDM2 and p53 expression were highly associated (r = 0.7161; p < 0.0001). The co-expression of p53-MDM2 was observed more frequently in malignant lesions (p < 0.0001) and helped characterize follicular patterned lesions distinguishing FVPTC from FA (p < 0.0001) and FVPTC from FTC (p < 0.0001). In addition, p53-MDM2 co-expression was associated with characteristics of less aggressiveness. It was more frequent in patients ≤45 years old (p = 0.0035), with unique tumors (p = 0.0095), tumors <2 cm (p < 0.0001), tumors without extrathyroid invasion (p = 0.0425), without metastasis at evolution (p = 0.0179), and in patients evolving free of disease after treatment (p = 0.0485). We suggest that p53-MDM2 co-expression profile analysis might help establishing diagnostic and determining prognostic of DTC patients.
Asunto(s)
Carcinoma Papilar/metabolismo , Inmunohistoquímica/métodos , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Nódulo Tiroideo/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Adulto , Carcinoma Papilar/diagnóstico , Carcinoma Papilar/cirugía , Carcinoma Papilar/ultraestructura , Diferenciación Celular , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Recurrencia , Estudios Retrospectivos , Sensibilidad y Especificidad , Glándula Tiroides/metabolismo , Glándula Tiroides/patología , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/cirugía , Nódulo Tiroideo/diagnóstico , Nódulo Tiroideo/cirugía , Nódulo Tiroideo/ultraestructuraRESUMEN
La trombosis se puede definir como un trastorno vascular que se presenta cuando se desarrolla un trombo que bloquea de forma total o parcial el interior de un vaso sanguíneo, ya sea una vena o una arteria. La trombofilia define a una alteración de la hemostasia que predispone al desarrollo de trombosis; sin embargo, la presencia de una trombofilia no implica necesariamente la aparición de un evento trombótico. La deficiencia de los inhibidores fisiológicos, como las proteínas C y S, constituyen factores de riesgo hereditarios y adquiridos que favorecen al desarrollo de trombosis. Se determinó la incidencia de deficiencia de estas proteínas de la coagulación en pacientes con historia obstétrica adversa, eventos de trombosis y otros eventos asociados. Se realizó un estudio longitudinal prospectivo en el período comprendido del 2011 al 2018, en un grupo de pacientes remitidos al Instituto de Hematología e Inmunología, a los que se les realizó la medición de los niveles plasmáticos de las proteínas C y S. En 133 pacientes (52,17 por ciento) se detectó deficiencia de proteína C (n=50), proteína S (n=66) o ambas (n=17). Las principales causas de realización de estos estudios fueron la historia obstétrica adversa y los eventos trombóticos y coincidieron con los eventos clínicos donde predominó alguna deficiencia. La deficiencia de proteína S tuvo mayor incidencia(AU)
Thrombosis is a vascular disorder appearing when a thrombus totally or partially blocks the inside of a blood vessel, be it a vein or an artery. Thrombophilia is a hemostatic alteration leading to thrombosis. However, the presence of thrombophilia does not necessarily imply the appearance of a thrombotic event. Deficiency in physiological inhibitors such as proteins C and S is a hereditary or acquired risk factor fostering thrombosis. Determination was made of the incidence of deficiency in these coagulation proteins in patients with an adverse obstetric history, thrombotic events and other associated disorders. A prospective longitudinal study was conducted in the period 2011-2018 of a group of patients referred to the Institute of Hematology and Immunology, who underwent measurement of their plasma levels of proteins C and S. A total 133 patients (52.17 percent) were found to be deficient in protein C (n=50), protein S (n=66) or both (n=17). The main reasons for the conduct of these studies were an adverse obstetric history and thrombotic events, which coincided with clinical disorders in which some sort of deficiency prevailed. Protein S deficiency was the most common(AU)
Asunto(s)
Humanos , Trombosis , Deficiencia de Proteína S , Deficiencia de Proteína C , Hematología , Estudios Prospectivos , Estudios LongitudinalesRESUMEN
SUMMARY OBJECTIVE This study aimed to investigate the predictive value of the newly defined C-Reactive Protein (CRP)/Albumin Ratio (CAR) in determining the development of atrial fibrillation (AF) in comparison with other inflammatory markers, such as Neutrophil/Lymphocyte (N/L) Ratio and Platelet/Lymphocyte (P/L) Ratio, in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery. METHODS The population of this observational study consisted of 415 patients undergoing CABG. The study cohort was subdivided into two groups based on the development of AF. Complete blood counts, serum CRP, and serum albumin levels were evaluated before the CABG. The CAR, N/L, and P/L ratios of all the patients were calculated. Predictors of postoperative AF were determined by multiple logistic regression analysis (MLRA). RESULTS During follow-up, 136 patients (32.8%) developed postoperative AF. With MLRA, independent risk factors for postoperative AF were determined as follows: fasting glucose level (OR: 1.01; 95 % CI: 1.00-1.01, P <0.001), age (OR: 1.12; 95 % CI: 1.07-1.17, P <0.001), left ventricle ejection fraction (OR: 0.90; 95 % CI: 0.87-0.94, P <0.001), male gender (OR: 3.32; 95 % CI: 1.39-7.90, P = 0.007), 24-hour drainage amount (OR: 1.004; 95 % CI: 1.002-1.005, P <0.001), and CAR (OR: 1.82; 95 % CI: 1.53-2.16, P <0.001). Receiver Operating Characteristic curve analysis showed that CAR (C-statistic: 0.75; 95% CI: 0.71-0.79, p< 0.001) was a significant predictor of AF. CONCLUSION Novel inflammatory marker CAR can be used as a reliable marker to predict the development of AF following CABG.
RESUMO OBJETIVO Este estudo teve como objetivo investigar o valor preditivo da recém-definida relação entre Proteína C-Reativa (PCR) e Albumina (CAR) na determinação do desenvolvimento de Fibrilação Atrial (FA) em comparação com outros marcadores inflamatórios, como proporção de Neutrófilos para Linfócitos (N/L) e relação Plaquetas/Linfócitos (P/L) em pacientes submetidos à Cirurgia de Revascularização do Miocárdio (CRM). MÉTODOS A população deste estudo observacional foi composta por 415 pacientes submetidos à cirurgia de revascularização do miocárdio. A coorte do estudo foi subdividida em dois grupos de acordo com o desenvolvimento da FA. Contagens sanguíneas completas, PCR sérica e albumina sérica foram obtidas antes da CRM. Os valores de CAR, relação N/L e relação P/L foram calculados. Os preditores de FA pós-operatória foram determinados por análise de regressão logística múltipla. RESULTADOS Durante o acompanhamento, 136 pacientes (32,8%) desenvolveram FA pós-operatória. Com análise de regressão logística múltipla, foram determinados os fatores de risco para FA pós-operatória: glicemia de jejum (OR: 1,01; IC 95%: 1,00-1,01, p<0,001), idade (OR: 1,12; IC 95%: 1,07-1,17, p<0,001), fração de ejeção do ventrículo esquerdo (OR: 0,90; IC 95%: 0,87-0,94, p<0,001), sexo masculino (OR: 3,32; IC 95%: 1,39-7,90, p=0,007), quantidade de drenagem de 24 horas (OR: 1,004; IC 95%: 1,002-1,005, p<0,001), CAR (OR: 1,82; IC 95%: 1,53-2,16, p<0,001). A análise da curva de características operacionais do receptor mostrou que o CAR (estatística C: 0,75; IC 95%: 0,71-0,79, p<0,001) foi um preditor significativo de FA. CONCLUSÃO O novo marcador inflamatório CAR é confiável para prever o desenvolvimento de FA após a operação de revascularização miocárdica.
Asunto(s)
Humanos , Masculino , Fibrilación Atrial , Complicaciones Posoperatorias , Proteína C-Reactiva , Puente de Arteria Coronaria , Factores de Riesgo , Curva ROCRESUMEN
SUMMARY OBJECTIVE This study aimed to investigate the predictive value of the newly defined C-Reactive Protein (CRP)/Albumin Ratio (CAR) in determining the development of atrial fibrillation (AF) in comparison with other inflammatory markers, such as Neutrophil/Lymphocyte (N/L) Ratio and Platelet/Lymphocyte (P/L) Ratio, in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery. METHODS The population of this observational study consisted of 415 patients undergoing CABG. The study cohort was subdivided into two groups based on the development of AF. Complete blood counts, serum CRP, and serum albumin levels were evaluated before the CABG. The CAR, N/L, and P/L ratios of all the patients were calculated. Predictors of postoperative AF were determined by multiple logistic regression analysis (MLRA). RESULTS During follow-up, 136 patients (32.8%) developed postoperative AF. With MLRA, independent risk factors for postoperative AF were determined as follows: fasting glucose level (OR: 1.01; 95 % CI: 1.00-1.01, P <0.001), age (OR: 1.12; 95 % CI: 1.07-1.17, P <0.001), left ventricle ejection fraction (OR: 0.90; 95 % CI: 0.87-0.94, P <0.001), male gender (OR: 3.32; 95 % CI: 1.39-7.90, P = 0.007), 24-hour drainage amount (OR: 1.004; 95 % CI: 1.002-1.005, P <0.001), and CAR (OR: 1.82; 95 % CI: 1.53-2.16, P <0.001). Receiver Operating Characteristic curve analysis showed that CAR (C-statistic: 0.75; 95% CI: 0.71-0.79, p< 0.001) was a significant predictor of AF. CONCLUSION Novel inflammatory marker CAR can be used as a reliable marker to predict the development of AF following CABG.
RESUMO OBJETIVO Este estudo teve como objetivo investigar o valor preditivo da recém-definida relação entre Proteína C-Reativa (PCR) e Albumina (CAR) na determinação do desenvolvimento de Fibrilação Atrial (FA) em comparação com outros marcadores inflamatórios, como proporção de Neutrófilos para Linfócitos (N/L) e relação Plaquetas/Linfócitos (P/L) em pacientes submetidos à Cirurgia de Revascularização do Miocárdio (CRM). MÉTODOS A população deste estudo observacional foi composta por 415 pacientes submetidos à cirurgia de revascularização do miocárdio. A coorte do estudo foi subdividida em dois grupos de acordo com o desenvolvimento da FA. Contagens sanguíneas completas, PCR sérica e albumina sérica foram obtidas antes da CRM. Os valores de CAR, relação N/L e relação P/L foram calculados. Os preditores de FA pós-operatória foram determinados por análise de regressão logística múltipla. RESULTADOS Durante o acompanhamento, 136 pacientes (32,8%) desenvolveram FA pós-operatória. Com análise de regressão logística múltipla, foram determinados os fatores de risco para FA pós-operatória: glicemia de jejum (OR: 1,01; IC 95%: 1,00-1,01, p<0,001), idade (OR: 1,12; IC 95%: 1,07-1,17, p<0,001), fração de ejeção do ventrículo esquerdo (OR: 0,90; IC 95%: 0,87-0,94, p<0,001), sexo masculino (OR: 3,32; IC 95%: 1,39-7,90, p=0,007), quantidade de drenagem de 24 horas (OR: 1,004; IC 95%: 1,002-1,005, p<0,001), CAR (OR: 1,82; IC 95%: 1,53-2,16, p<0,001). A análise da curva de características operacionais do receptor mostrou que o CAR (estatística C: 0,75; IC 95%: 0,71-0,79, p<0,001) foi um preditor significativo de FA. CONCLUSÃO O novo marcador inflamatório CAR é confiável para prever o desenvolvimento de FA após a operação de revascularização miocárdica.
Asunto(s)
Humanos , Masculino , Fibrilación Atrial , Complicaciones Posoperatorias , Proteína C-Reactiva , Puente de Arteria Coronaria , Factores de Riesgo , Curva ROCRESUMEN
BACKGROUND: Biomarker combinations can improve timely diagnosis and survival. OBJECTIVE: To determine the usefulness of serum procalcitonin concentration (PCT), C-reactive protein (PCR) and the PCR / PCT index as predictors of mortality. METHOD: Retrospective study of patients diagnosed with abdominal sepsis during the period from April 2017 to February 2018. RESULTS: We included 182 cases. In the survivors, the mean PCR was 170 and procalcitonin (PCT) 10.5. In the deceased, the mean of C-reactive protein (CRP) was 328 and that of PCT was 17.6. When applying the student's t-test for independent samples, it was found that these differences were significant for PCR (p = 0.001); however, for PCT it was not significant (p = 0.460). Afterwards, the PCR/PCT index was studied, as a predictor of mortality, in the deceased cases a PCR/PCT score of 7534 (standard deviation [SD]: 19,303) and for survivors of 538 (SD:805) (p = 0.001) was obtained. CONCLUSION: CRP is associated with mortality, serum PCT does not correlate with mortality. The PCR/PCT index seems to be a better indicator to predict mortality in patients with abdominal sepsis due to secondary peritonitis.
ANTECEDENTES: Las combinaciones de biomarcadores pueden mejorar el diagnóstico oportuno y la supervivencia. OBJETIVO: Determinar la utilidad de la concentración sérica de procalcitonina (PCT), la proteína C reactiva (PCR) y el índice PCR/PCT como predictores de mortalidad. MÉTODO: Estudio retrospectivo de pacientes con diagnóstico de sepsis abdominal durante el periodo de abril de 2017 a febrero de 2018. RESULTADOS: Se incluyeron 182 casos. En los sobrevivientes, la media de los valores de PCR fue de 170 y la de PCT fue de 10.5. En los fallecidos, la media de los valores de PCR fue de 328 y la de PCT fue de 17.6. Al aplicar el estadístico t de Student para muestras independientes se obtuvo que estas diferencias resultaron significativas para la PCR (p = 0.001), pero no para la PCT (p = 0.460). Posteriormente se estudió el índice PCR/PCT como predictor de mortalidad: en los fallecidos se obtuvo un valor de 7534 (desviación estándar [DE]:± 19,303) y en los sobrevivientes de 538 (DE± 805) (p = 0.001). CONCLUSIÓN: La PCR se asocia con la mortalidad, mientras que la PCT no guarda relación con la mortalidad. El índice PCR/PCT parece ser un mejor indicador para predecir la mortalidad en los pacientes con sepsis abdominal por peritonitis secundaria.
Asunto(s)
Proteína C-Reactiva/análisis , Polipéptido alfa Relacionado con Calcitonina/sangre , Sepsis/sangre , Sepsis/mortalidad , Abdomen , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios RetrospectivosRESUMEN
ABSTRACT Acute mesenteric ischemia is a medical emergency that accounts for less than 1/1000 hospital admissions. The disease affects adults older than 50 years predominantly with cardiac compromise, in whom the presence of acute abdominal pain is the cardinal manifestation, and should make the clinician suspect this entity. Its presentation in adolescents is unusual; therefore, in these cases, the possibility of an underlying thrombophilia should be part of the differential diagnosis. The case is presented here of a young female with a protein C and S deficiency as the cause of mesenteric thrombosis.
RESUMEN La isquemia mesentérica aguda es una urgencia médica que se presenta en menos de 1/1.000 ingresos hospitalarios. Es una entidad clínica infrecuente, predominante en adultos mayores de 50 arios con afectación cardíaca, en quienes la presencia de dolor abdominal agudo es la manifestación cardinal y debería hacer sospechar dicho diagnóstico. La presentación en adolescentes es inusual, por lo que, en estos casos, la posibilidad de una trombofilia subyacente debe formar parte del diagnóstico diferencial. Presentamos el caso de una paciente joven con deficiencia de proteínas C y S como agente causal de trombosis mesentérica.
Asunto(s)
Humanos , Femenino , Adolescente , Deficiencia de Proteína , Trombosis , Vasculitis , Dolor Abdominal , Urgencias Médicas , Proteína C , Isquemia MesentéricaRESUMEN
Objetivo: Evaluar la influencia de la altura en los niveles de proteína C reactiva (PCR) en adultos con adiposidad visceral abdominal. Materiales y métodos: Se realizó un estudio cuantitativo con diseño cuasi-experimental, que incluyó veinticuatro estudiantes de medicina de la Universidad Nacional de Trujillo, sexo masculino, seleccionados de manera no probabilística por conveniencia y sujeto participante, que fueron evaluados a 0 y 4386 m s. n. m. y clasificados de acuerdo al grado de adiposidad visceral abdominal: normal (G1) y elevada (G2). Resultados: El nivel de PCR de G1 en relación a G2 no tuvo diferencia significativa. Respecto a los niveles de PCR de G2 se empleó la prueba no paramétrica de Wilcoxon y para G1 se usó la prueba T-student, evidenciándose una significancia en ambos casos. Conclusiones: Las variaciones de los niveles de PCR en altura con respecto al basal de ambos grupos fueron significativos
Objective: To evaluate the influence of high altitude on C-reactive protein (CRP) levels in adults with abdominal visceral adiposity. Materials and methods: A quantitative study with quasi-experimental design, which included twenty-four (24) male medical students from the National University of Trujillo, selected by non-probability convenience sampling and study subject, evaluated at 0 and 4,386 m.a.s.l., and classified according to their degree of abdominal visceral adiposity: normal (G1) and high (G2). Results: The CRP level of G1 in relation to G2 showed no significant difference. Regarding CRP levels, Wilcoxon rank-sum (non-parametric) test was used for G2 and Student´s t-test was used for G1, with significance being shown in both cases. Conclusions: Variations on CRP levels in high altitude compared to sea level in both groups were significant
RESUMEN
Activated Protein C (APC) is a serine-protease that displays antithrombotic and anti-inflammatory properties. In addition, cleavage of protease-activated receptor 1 (PAR1) by APC exerts endothelial cytoprotective actions. The effects of APC on endothelial cells may be reproduced by TR47, a PAR1-based peptide that mimics the novel N-terminus of PAR1 generated upon cleavage at Arg-46 by APC. In this study we demonstrate that wild-type APC and its signaling-proficient mutant, APC-2Cys (which has dramatically reduced anticoagulant activity), display similar inhibitory effects towards the transendothelial migration of A375 human melanoma cells. Consistent with this observation, APC and APC-2Cys significantly reduced the in vivo metastatic potential of the B16F10 murine melanoma cells. TR47 recapitulated the in vitro and in vivo protective profiles of APC and APC-2Cys. Treatment of EA.hy926 endothelial cells with TR47 (20 µM) significantly decreased the A375 cell migration. In addition, treatment of C57/BL6 mice with a single TR47 dose (125 µg/animal) strongly reduced the metastatic burden of B16F10 cells. Together, our results suggest that protection of the endothelial barrier by APC/TR47-mediated signaling pathways might be a valuable therapeutic approach to prevent metastasis.
Asunto(s)
Movimiento Celular/efectos de los fármacos , Transformación Celular Neoplásica/efectos de los fármacos , Melanoma/metabolismo , Melanoma/secundario , Péptidos/administración & dosificación , Receptor PAR-1/química , Animales , Línea Celular Tumoral , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Humanos , Melanoma/patología , Ratones , Ratones Endogámicos C57BL , Invasividad Neoplásica/patología , Péptidos/químicaRESUMEN
Activated protein C resistance (aPCR) phenotypes represent around 20% of the laboratory findings in Mexican Mestizos having suffered thrombosis and displaying clinical markers of thrombophilia. In a single institution for a 276-month period, 96 Mexican mestizos with a history of thrombosis and clinical markers of a primary thrombophilic state were prospectively studied to identify a thrombophilic condition. An abnormal aPCR phenotype was identified in 18 individuals. Evaluation of those with an abnormal aPCR phenotype, identified that 44% had factor V Leiden mutation, 22% increased levels of factor VIII, 16% anti-phospholipid antibodies and 6% a lupus anticoagulant. In the remaining 22%, the use of direct oral anticoagulants (DOACs) in the past period of 12-24 h was recorded. We found significant associations between abnormal aPCR phenotype and the factor V Leiden mutation (p = 0022), between abnormal aPCR phenotype and the use of DOACs (p = 0.006) and between antiphospholipid antibodies and lupus anticoagulant (p < 0.0001). These data are consonant with those observed in other populations and further identify that consideration be given to identifying whether individuals are being treated with the novel DOACs when conducting laboratory studies oriented to identify the etiology of thrombosis.
RESUMEN
INTRODUCTION: Hemostasis protects upon the occurrence of vascular endothelial damage, with involving of different factors. The interaction of these factors in older adults is poorly known, and has been associated with different disorders. Therefore, we determined the activity of coagulation factors (CF), anticoagulant proteins (AP), and plasminogen (Plg), as well as the frequency of deficiencies of these proteins in a population of healthy Mexican older adults (OA). METHODS: CF (I, II, V, VII, VIII, IX, X, and XI y XII), AP [protein C (PC), protein S (PS), and antithrombin (AT)], and Plg were determined from 244 plasma samples of OA using commercial kits in a coagulometer ACL Elite Pro. RESULTS: A total of 139 women and 105 men were under study. They were divided into age range groups (50-59, 60-69, 70-79, and Ë80 years). Activity of CF, AP, and Plg was determined. Frequencies of CF, AP, and Plg activity values were obtained for each age group according to gender. Differences were found between both frequencies for each protein. CONCLUSION: Significant differences were found, so it is recommended to establish reference values (RV) for the activity of fibrinogen and FX by decade and gender, FVII and FXII by gender, FII, FV, FVIII, PC, PS, and Plg by decade, whereas for FIX, FXI, and AT, they are not modified by age or gender, so the RV described for adult Mexican population can be used. It is important to integrate these results into established diagnostic algorithms, which can be taken into account to provide an accurate diagnosis and treatment for patients with suspected hemorrhagic or thrombotic processes, as well as suggest those habits that improve their quality of life, to maintain optimal health and prevent thrombotic and hemorrhagic events.
Asunto(s)
Envejecimiento/sangre , Anticoagulantes/sangre , Factores de Coagulación Sanguínea/metabolismo , Hemostasis , Plasminógeno/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Pruebas de Coagulación Sanguínea/métodos , Endotelio Vascular/lesiones , Endotelio Vascular/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Introducción: la Organización Mundial de la Salud afirma que las enfermedades del corazón y los accidentes cerebrovasculares son la primera causa de muerte en el mundo. Se prevé que en 2020 sean la primera causa de defunción y discapacidad. Objetivo: sistematizar las aplicaciones de la tabla de estimación de riesgo cardiovascular de Framingham, variables y biomarcadores de riesgo cardiovascular. Métodos: se realizó una revisión bibliográfica, análisis y categorización de diferentes artículos en las bases de datos Scielo, Pub Med, Redalyc y Medigraphic, los términos clave para la búsqueda fueron: riesgo cardiovascular, evaluación, y tabla de Framingham; combinados con infarto agudo al miocardio, angina y accidente cerebrovascular. Se establecieron como límite aquellos artículos publicados posteriores al año 2005. Conclusiones: la literatura disponible sobre estimación del riesgo cardiovascular en poblaciones sanas es moderada, y se realiza utilizando diversas tablas de estimación de riesgo, las que en su mayoría derivan del estudio Framingham, el que considera diferentes factores de riesgo cardiovascular medulares tales como: edad, sexo, colesterol total, colesterol HDL, presión arterial y tabaquismo, estos son universales y de bajo costo al momento de ser medidos, por lo que la aplicación de este score es uno de los más utilizados pero no el único. Las herramientas de medición de riesgo tales como la tabla de Framingham, índice tobillo brazo, proteína c ultra sensible, y homocisteína, juegan un papel fundamental en la prevención primaria de la enfermedad cardiovascular siendo necesarias para minimizar el aumento en la morbimortalidad cardiovascular en México y en el mundo(AU)
Introduction: The World Health Organization states that heart disease and stroke are the leading cause of death worldwide. It is expected to be the leading cause of death and disability in 2020. Objective: Sistematize applications estimation table Framingham cardiovascular risk, variables and biomarkers of cardiovascular risk. Methods: A literature review, analysis and categorization of different items in Scielo data bases, Pub Med, Redalyc and Medigraphic, the key terms for the search was conducted were: cardiovascular risk, assessment, and Framingham table; combined with acute myocardial infarction angina and stroke. Those articles published after the year 2005 were set as a limit. Conclusions: The literature on estimation of cardiovascular risk in healthy populations is moderate and is performed using various tables estimation risk, most of which derive from the Framingham study identified different factors medullary cardiovascular risk such as: age, sex, total cholesterol, HDL cholesterol, blood pressure and smoking, these are universal and inexpensive at the time of being measured, so that the application of this score is one of the most used but not alone. The tools of risk measurement such as the Framingham table, ankle - brachial index, protein c ultra-sensitive, and homocysteine play a fundamental role in primary prevention of cardiovascular disease being necessary to minimize the increase in cardiovascular morbidity and mortality in México and the world(AU)
Asunto(s)
Humanos , Literatura de Revisión como Asunto , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/prevención & control , Factores de Riesgo , Bases de Datos BibliográficasRESUMEN
OBJECTIVE: To compare outcomes of infants and children who underwent lung transplantation for genetic disorders of surfactant metabolism (SFTPB, SFTPC, ABCA3, and NKX2-1) over 2 epochs (1993-2003 and 2004-2015) at St Louis Children's Hospital. STUDY DESIGN: We retrospectively reviewed clinical characteristics, mortality, and short- and long-term morbidities of infants (transplanted at <1 year; n = 28) and children (transplanted >1 year; n = 16) and compared outcomes by age at transplantation (infants vs children) and by epoch of transplantation. RESULTS: Infants underwent transplantation more frequently for surfactant protein-B deficiency, whereas children underwent transplantation more frequently for SFTPC mutations. Both infants and children underwent transplantation for ABCA3 deficiency. Compared with children, infants experienced shorter times from listing to transplantation (P = .014), were more likely to be mechanically ventilated at the time of transplantation (P < .0001), were less likely to develop bronchiolitis obliterans post-transplantation (P = .021), and were more likely to have speech and motor delays (P ≤ .0001). Despite advances in genetic diagnosis, immunosuppressive therapies, and supportive respiratory and nutritional therapies, mortality did not differ between infants and children (P = .076) or between epochs. Kaplan-Meier analyses demonstrated that children transplanted in epoch 1 (1993-2003) were more likely to develop systemic hypertension (P = .049) and less likely to develop post-transplantation lymphoproliferative disorder compared with children transplanted in epoch 2 (2004-2015) (P = .051). CONCLUSION: Post-lung transplantation morbidities and mortality remain substantial for infants and children with genetic disorders of surfactant metabolism.